By Eileen Bailey on May 3, 2022
“It looks to be a novel drug predicated for those women with refractory recurrent yeast infections,” says Kecia Gaither MD, MPH, FACOG, Director of Perinatal Services at NYC Health. “The drug, primarily based on the recommendations should be utilized in a particular cohort of women — postmenopausal women and women who have had a hysterectomy.”
Click HERE for the full article.
